This was exactly what I wanted, but I wanted this over three months. But every time I looked in the mirror, my body was ...

With airstrikes on Ukraine’s cathedrals and temples, and targeted killings of religious leaders, Russia’s Vladimir Putin is ...

LAB rallies 19% as whale wallets stack longs and target $19. Whale longs hold 92% profitability while shorts sit deeply underwater. RSI nears overbought as low volume raises caution on the move. LAB ...

A chaotic water inflation experiment that takes toys to the breaking point. Huge pressure builds up before sudden explosive moments. #WaterChallenge #Viral #Experiment US says it won't renew CUSMA.

Here’s what you’ll learn when you read this story: The French cargo ship SS Grandcamp was loaded with over 2,000 tons of ammonium nitrate fertilizer in Texas City, TX. When the ammonium nitrate ...

The investigative minds at How to Survive uncover the hidden dangers of exploding smartphones and the practical safety hacks that can prevent serious injury. AFL great Nicky Winmar guilty of smashing ...

Informed by science from the Smithsonian Astrophysical Observatory and astronomers worldwide, this “documentary that you can walk through” visualizes the cosmos in a 3-D introduction to the universe ...

The data is in, and consumer-price inflation is now sitting at a three-year high on an annual basis, which will make it tough for the Fed to cut rates. Stocks are off to a lower start. Alarm bells are ...

Lab analyst Diana Wendelin gently adjusts a slide under a microscope. An enlarged image of a tick comes into focus on her computer screen. “So, the first thing I'm looking at is called the scutum.

'Among those most educated, India’s birth rate fell below replacement many years ago,' Elon Musk wrote on X. Tesla CEO Elon Musk’s recent X post on India’s falling birth rate has sparked a sharp ...

No personnel were harmed in the incident, the company said on social media, calling the explosion an ‘anomaly’ Nasa’s plans to build a lunar base and return humans to the moon in the next two years ...

A concerning number of deaths and lack of survival benefit in a confirmatory trial have raised questions about the approval status for the antibody-drug conjugate loncastuximab tesirine (Zynlonta) in ...